KOMUNIKATY PRASOWE
Positive interim data from Phase Ib proof-of-concept trial will be presented at the IPPF Scientific Symposium on Pemphigus and Pemphigoid and at EADV Congress 2026…
Favorable safety and tolerability profile, with rapid onset of clinical activity and therapeutic effects observed in patients with LAD Data support the start of a…
FAVORABLE SAFETY, TOLERABILITY, PHARMACOKINETIC AND PHARMACODYNAMIC PROFILES VALIDATE AND SIGNIFICANTLY DE-RISK THE PROGRAM SUPPORTS THE FEASIBILITY OF INTRAVENOUS AND SUBCUTANEOUS DOSING REGIMENS IN UPCOMING CLINICAL…
JJP Biologics confirms the mechanism of action and immunostimulatory activity of JJP-1008, a potential first-in-class therapeutic anti-CD270 monoclonal antibody. JJP-1008 selectively inhibits the immunosuppressive activity…
JJP Biologics confirms the mechanism of action and immunostimulatory activity of JJP-1008, a potential first-in-class therapeutic anti-CD270 monoclonal antibody. JJP-1008 selectively inhibits the immunosuppressive activity…
JJP Biologics announces the start of the MAD part in the ongoing Phase I Clinical Trial of a new investigational medicinal product JJP-1212, a first-in-class…